Markets
markets

Eli Lilly slips after UK declines to cover Alzheimer’s drug

Eli Lilly fell about 3% on Friday after the United Kingdom’s national health provider said it wouldn’t cover the company’s new Alzheimer’s treatment.

The benefits of the injection are too small to justify the cost, the UK’s National Institute for Health and Care Excellence said on Thursday. The drug, Kisunla, is the first to have shown it can slow the progression of Alzheimer’s, but is expensive and comes with safety risks.

The market for the blockbuster drug may be smaller than initially expected. While Medicaid in the US does cover monthly injections, the European Union in May declined to approve the drug over risks of brain swelling.

Analysts polled by FactSet expect the drug to generate $153.3 million in revenue for Lilly this year. That’s down from the $173.8 million consensus in March.

The market for the blockbuster drug may be smaller than initially expected. While Medicaid in the US does cover monthly injections, the European Union in May declined to approve the drug over risks of brain swelling.

Analysts polled by FactSet expect the drug to generate $153.3 million in revenue for Lilly this year. That’s down from the $173.8 million consensus in March.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.